Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial

Journal:

Nature Medicine

Published:

2025-10-18

DOI:

10.1038/s41591-025-04022-w

Affiliations:

8

Authors:

11

Go to article

Institutions	Authors	Share
Arcus Biosciences, United States of America (USA)	5.000000	0.45
Seoul National University Hospital (SNUH), South Korea	1.000000	0.09
Sarah Cannon Research Institute (SCRI), United States of America (USA)	1.000000	0.09
UCLA Health, United States of America (USA)	1.000000	0.09
Gilead, United States of America (USA)	1.000000	0.09
Yonsei Cancer Hospital, South Korea	1.000000	0.09
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)	0.500000	0.05
Weill Cornell Medicine, United States of America (USA)	0.500000	0.05

Interested in Oncology and Carcinogenesis?